ArticleRheumatology international2013
Follow-up of primary Sjogren's syndrome patients presenting positive anti-cyclic citrullinated peptides antibody.
Article in Rheumatology international, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- 2023 International Rome consensus for the nomenclature of Sjögren disease.Nature reviews. Rheumatology · 2025Article
- Comparative Analysis of Glandular and Extraglandular Manifestations in Primary and Secondary Sjögren's Syndrome: A Study in Two Academic Centers in North-East Romania.Diagnostics (Basel, Switzerland) · 2024Article
- Polyarthritis in Sjögren's Syndrome: Difficulties in Distinguishing Extraglandular Manifestation and Associated Rheumatoid Arthritis.Diagnostics (Basel, Switzerland) · 2024Article
- Emerging biologic frontiers for Sjogren's syndrome: Unveiling novel approaches with emphasis on extra glandular pathology.Frontiers in pharmacology · 2024Review
- Autoimmune markers in screening for orbital inflammatory disease.Eye (London, England) · 2023Article
- Total Knee Arthroplasty in Patients with Primary Sjögren's Syndrome: A Retrospective Case-Control Study Matched Patients without Rheumatic Diseases.Journal of clinical medicine · 2022Article
- Not all autoantibodies are clinically relevant. Classic and novel autoantibodies in Sjögren's syndrome: A critical review.Frontiers in immunology · 2022Review
- Musculoskeletal Manifestations in Sjogren's Syndrome: An Orthopedic Point of View.Journal of clinical medicine · 2021Review
- Long-term follow-up of patients with anti-cyclic citrullinated peptide antibody-positive connective tissue disease: a retrospective observational study including information on the HLA-DRB1 allele and citrullination dependency.Arthritis research & therapy · 2020Observational
- Characterizing hand and wrist ultrasound pattern in primary Sjögren's syndrome: a case-control study.Clinical rheumatology · 2020Article
- Prognostic value of Sjögren's syndrome autoantibodies.Journal of laboratory and precision medicine · 2018Article
- Criteria sets for primary Sjogren's syndrome are not adequate for those presenting with extraglandular organ involvements as their dominant clinical features.Rheumatology international · 2017Article
- Primary Sjögren's syndrome: clinical phenotypes, outcome and the development of biomarkers.Immunologic research · 2017Review
- Reviewing primary Sjögren's syndrome: beyond the dryness - From pathophysiology to diagnosis and treatment.International journal of medical sciences · 2017Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anti-cyclic citrullinated peptide antibody (anti-CCP antibody) is very useful for the diagnosis of rheumatoid arthritis (RA) and is associated with articular erosions. The specificity of anti-CCP antibody in the diagnosis of RA has been reported to be about 95 %. Because of its higher specificity in RA, we assessed the clinical features of primary Sjogren's syndrome (pSS) who were positive for anti-CCP antibody. We assessed the clinical features of 405 pSS patients. After 60 (range 7-98) months, 23 (5.6 %) patients previously diagnosed with pSS had progressed to RA. Comparing the anti-CCP positive group with the negative group, laboratory test results for anti-CCP titer and rheumatoid factor positivity with respect to clinical outcome and progression to RA, arthralgia and arthritis were significantly different. Multivariate regression analysis also showed that anti-CCP antibody titer was independently associated with progression to RA. The odds ratio of anti-CCP positivity in terms of progression to RA was 2.5 (95 % CI 1.7-3.7). Testing for anti-CCP antibody in pSS patients with arthritis may allow for the prediction of progression to RA.
Indexed as
Identifiers
23179261What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.